nervapax ApS
Private limited companyCVR 44342170HjallerupActive
nervapax ApS is a private limited company, based in Hjallerup, active in research and experimental development on natural sciences and engineering, founded in 2023. The company went from a profit in 2024 to a loss of DKK 151k in 2025. Equity fell to DKK 445k in 2025.
Key figures · financial year 2025
What has changed
calculated from recorded figures and datesFinancials: 2025 against 2024
- Gross profit fell 102% (2024 → 2025), to −DKK 29,066.
- Net profit went from a profit of DKK 556k to a loss of DKK 151k (2024 → 2025).
- Equity fell 25% (2024 → 2025), to DKK 445k.
Registrations, last 24 months
- 01/01/2025: Industry changed to Research and experimental development on natural sciences and engineering (721000)
Calculated from the latest two annual reports in sequence and from registrations in CVR. A figure that is missing in either year gives no line, and we derive no figures.
Financial statements
Financial years 2024–2025 · amounts in DKK thousandEquity and net profit
| 2024 | 2025 | Change | |
|---|---|---|---|
| Revenue | not stated | not stated | – |
| Gross profit | 1,427 | −29 | −102% |
| Operating profit (EBIT) | 701 | −192 | −127.4% |
| Profit before tax | 698 | −193 | −127.6% |
| Net profit | 556 | −151 | −127.2% |
| Total assets | 1,073 | 862 | −19.7% |
| Equity | 596 | 445 | −25.3% |
| Liabilities | 310 | 291 | −6.1% |
| Cash and cash equivalents | 255 | 72 | −71.9% |
| Average number of employees | 2 | 0 | −100% |
Source: annual reports filed with the Danish Business Authority (XBRL). Figures for the company (not the group); change is the latest year against the year before. “–” means the figure is not stated in the annual report. Revenue is not stated for 2024, 2025: smaller companies may omit it, and we do not derive it from other figures.
Download the figures as CSV · free with an account, amounts in whole DKK
Annual reports
2 financial years| Financial year | Period | Published | Figures for | Documents |
|---|---|---|---|---|
| 2025 | 01/01/2025 – 31/12/2025 | 01/07/2026 | The company | PDF not statedXBRL |
| 2024 | 02/10/2023 – 31/12/2024 | 04/07/2025 | The company | PDFXBRL |
The figures from all the annual reports are shown on this page. The documents themselves (PDF and XBRL, the machine-readable edition) are downloaded with a Pro account: sign in or create a free account, and then choose Pro. XBRL is the edition the figures on the page are read from.
Employees
monthly figures from CVRPosition in the industry
431 companies in the databaseComparison with the other companies in research and experimental development on natural sciences and engineering based on the latest financial year.
Industry median: gross profit DKK 616k, net profit −DKK 892k, equity DKK 2m, 5 employees.
Compared with similar companies
size, age and company form| Group | Gross profit | Equity |
|---|---|---|
| Companies with fewer than 20 employees69,967 companies in the comparison | No. 64,385of 69,742 Better than 8% | No. 43,343of 69,964 Better than 38% |
| Same industry and fewer than 20 employees329 companies in the comparison | No. 184of 323 Better than 43% | No. 180of 329 Better than 45% |
| Companies that are founded within the last five years16,662 companies in the comparison | No. 15,394of 16,614 Better than 7% | No. 6,106of 16,661 Better than 63% |
| All companies of type ApS66,508 companies in the comparison | No. 61,884of 66,379 Better than 7% | No. 39,248of 66,505 Better than 41% |
The rank is calculated among companies in the database with a figure for the latest financial year, and is shown only for groups of at least ten companies.
Compare with the industry
Research and experimental development on natural sciences and engineering- nervapax ApS−DKK 29,066
- Carlsberg A/SDKK 40.2bn
- Zealand Pharma A/SDKK 9.2bn
- nervapax ApS−DKK 151k
- Carlsberg A/SDKK 7bn
- Zealand Pharma A/SDKK 6.5bn
- nervapax ApSDKK 445k
- Carlsberg A/SDKK 30.7bn
- Zealand Pharma A/SDKK 14.8bn
- nervapax ApS2
- Carlsberg A/S107
- Zealand Pharma A/S569
Latest financial year per company. Choose up to three companies from the largest in the industry.
Owners and group
from the Public Ownership Register- nervapax holding ApS100%
Management
2 active registrationsExecutive management
| Name | Role | Appointed |
|---|---|---|
| Fridel de Fries Laursen | Director | 02/10/2023 |
| Meike Claudia Sieburg | Director | 02/10/2023 |
- Founders
- nervapax holding ApS
Signing rule: Selskabet tegnes af to direktører i forening.
Address and production units
1 active production unitsVestergade 94
9320 Hjallerup
| Production unit | Address | Employees | P number |
|---|---|---|---|
| nervapax ApS | Vestergade 94, 9320 Hjallerup | 2 | 1029701322 |
Purpose
Selskabets formål er at udvikle et medtech apparat til smertelindring, samt enhver anden aktivitet der efter ledelsens skøn står i forbindelse hermed.
The purpose is quoted from the register in Danish.
Changes year by year
7 registered events20261 changeaccounts 1
- AccountsAnnual report for 2025 published
20252 changesaccounts 1 · industry 1
- AccountsAnnual report for 2024 published
- IndustryIndustry changed to Research and experimental development on natural sciences and engineering (721000)
20234 changesfounded 1 · management 2 · ownership 1
- FoundedRegistered as nervapax ApS
- ManagementFridel de Fries Laursen appointed director
- ManagementMeike Claudia Sieburg appointed director
- Ownershipnervapax holding ApS registered as owner (100%)
Related companies
Largest in the industry
- Carlsberg A/SDKK 40.2bn
- Zealand Pharma A/SDKK 9.2bn
- Gubra A/SDKK 2.6bn
- Vestas Wind Systems A/SDKK 2.5bn
- Bang & Olufsen A/SDKK 1.4bn
- 3shape A/SDKK 1.3bn
Source and updates
The information comes from the Danish Central Business Register (Danish Business Authority) and from annual reports filed with the Danish Business Authority. Last synchronised 24/10/2026.